Influenza A and B virus replication

Influenza A and B virus replication in cell culture refers to the complete biological cycle of the influenza virus within a laboratory cellular environment, rather than a single molecular target (NIH, 2023). This process encompasses several critical stages: viral attachment to sialic acid receptors via hemagglutinin, entry through endocytosis, uncoating mediated by the M2 ion channel, and the replication of the viral RNA genome within the nucleus (Nature Reviews Microbiology, 2018). Following protein synthesis and assembly, new virions are released from the host cell through the action of the neuraminidase enzyme (StatPearls, 2023). In drug discovery, this 'target' represents a phenotypic screening approach where compounds are evaluated for their ability to inhibit the overall production of infectious virus. Clinically relevant drugs like oseltamivir and baloxavir marboxil target specific viral enzymes—neuraminidase and the cap-dependent endonuclease, respectively—to disrupt this replication cycle and treat influenza infections (FDA, 2018). Because it describes a multi-step biological process involving an entire organism rather than a specific protein or receptor, it is considered an organism-level or phenotypic target in pharmacological databases.

Other names

Influenza virus replicationViral replication in cell cultureInfluenza phenotypic assayInfluenza A and B replication cycle

Inhibition of viral neuraminidase, viral polymerase complex (cap-dependent endonuclease), or M2 ion channel proteins to prevent the production and release of infectious progeny.